Orgasm Inc.

Last updated
Orgasm Inc.
Orgasm Inc Poster.jpg
Directed by Liz Canner
Produced byLiz Canner
Edited byLiz Canner, Sandra Christie, Jeremiah Zagar
Music byAlex Barnett, Don Glasgo, Gusano, Stephanie Olmanni
Distributed byFirst Run Features
Release date
November 2009
Running time
80 min
CountryUnited States
LanguageEnglish

Orgasm Inc. (2009) is the first feature documentary by award-winning director Liz Canner. It premiered at the Hot Docs Documentary Film Festival. [1]

Contents

In the documentary, filmmaker Liz Canner takes a job editing erotic movies for a drug trial for a pharmaceutical company called Vivus. Her employer is developing what they hope will be the first Viagra drug for women that wins FDA approval to treat a new disease: female sexual dysfunction (FSD). Many women suffer from this, as males suffer erectile dysfunctions. However, women's issues with this sexual matter have been seen to be not as important as those of their partner. Over time women have become more involved in their sexual experiences and want to gain just as much from it as their partners by wanting to cure the issue of not being able to reach an orgasm. Liz gains permission to film the company's work in general for her own documentary. Initially, she plans to create a movie about science and pleasure but she soon begins to suspect that her employer, along with a cadre of other medical companies, might be trying to take advantage of women (and potentially endanger their health) in pursuit of billion dollar profits.

The film continues from Vivus onto the more general question of whether there is a solid scientific foundation to medical industry claims about what constitutes "healthy" female sexuality and whether drugs and surgery are a suitable first-line approach to obtaining it. The film documents an emerging medical industry intent on convincing as large a market of women as possible that they have medical problems, and that those problems are best solved by expensive and dangerous medical treatments. Orgasm Inc. is presented as a look inside the medical industry and the marketing campaigns that are literally and figuratively reshaping the public's lives concerning health, illness, desire, and orgasm.

Release

Orgasm Inc. premiered at the Hot Docs Documentary Film Festival in 2009. It has shown in over 70 film festivals all over the world, including the International Documentary Film Festival Amsterdam (IDFA), the Big Sky Documentary Film Festival, and the Independent Film Festival of Boston. The film has also been broadcast on national television in Canada, Finland, France, Italy, Brazil, Israel, Spain, Poland, the Netherlands, United States and Japan. The film was picked up by First Run Features who released the movie in cinemas in the U.S. on February 11, 2011.

Critical reception

Since its release in 2009, Orgasm Inc. has received numerous awards, including the Best Feature award at the Vermont International Film Festival, the 2nd Best Feature award at the KOS International Health Film Festival, the Best Documentary Award at the Southeast New England (SENE) Film, Music, and Arts Festival, and the Best Feature Award at the Newburyport Documentary Film Festival.

The New York Times named it a "Critic's Pick" and said that it was "as entertaining as it was revelatory". [2] The Hot Docs Film Festival called it an "extraordinary behind-the-scenes access reveals a drug company's fevered race to develop the first FDA-approved Viagra for women — and offers a humorous but sobering look inside the cash-fueled pharmaceutical industry".

Newsweek said "[Orgasm Inc.] is a desperately needed antidote to all the hype generated by pharmaceutical companies pursuing their holy grail: a female Viagra." [3]

The Times called it "an extraordinary, revelatory documentary about female desire and the pharmaceutical industry".

In addition, articles about the movie and quotes from director Liz Canner have appeared internationally in hundreds of articles and blogs and dozens of TV shows and radio programs such as ABC News, Vogue, Newsweek, the Times of London, the Wall Street Journal, the BBC World Service, Public Radio, the LA Times, the Guardian, Cosmopolitan South Africa, Glamour Brazil, etc. This media attention has helped to raise serious questions about the pharmaceutical industries involvement with creating and marketing diseases. It has also protected millions of women from being misled into believing that they have FSD and they need to be treated with a drug (that could potentially harm them).

Related Research Articles

<span class="mw-page-title-main">Sildenafil</span> Medical drug for erectile dysfunction and pulmonary hypertension

Sildenafil, sold under the brand name Viagra, among others, is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is unclear if it is effective for treating sexual dysfunction in women. It is taken by mouth or by injection into a vein. Onset is typically within twenty minutes and lasts for about two hours.

Anorgasmia is a type of sexual dysfunction in which a person cannot achieve orgasm despite adequate stimulation. Anorgasmia is far more common in females than in males and is especially rare in younger men. The problem is greater in women who are post-menopausal. In males, it is most closely associated with delayed ejaculation. Anorgasmia can often cause sexual frustration.

<span class="mw-page-title-main">Tadalafil</span> Medication used to treat erectile dysfunction

Tadalafil, sold under the brand name Cialis among others, is a medication used to treat erectile dysfunction (ED), benign prostatic hyperplasia (BPH), and pulmonary arterial hypertension. It is taken by mouth. Onset is typically within half an hour and the duration is up to 36 hours.

Sexual dysfunction is difficulty experienced by an individual or partners during any stage of normal sexual activity, including physical pleasure, desire, preference, arousal, or orgasm. The World Health Organization defines sexual dysfunction as a "person's inability to participate in a sexual relationship as they would wish". This definition is broad and is subject to many interpretations. A diagnosis of sexual dysfunction under the DSM-5 requires a person to feel extreme distress and interpersonal strain for a minimum of six months. Sexual dysfunction can have a profound impact on an individual's perceived quality of sexual life. The term sexual disorder may not only refer to physical sexual dysfunction, but to paraphilias as well; this is sometimes termed disorder of sexual preference.

<span class="mw-page-title-main">Bremelanotide</span>

Bremelanotide, sold under the brand name Vyleesi, is a medication used to treat low sexual desire in women. Specifically it is used for low sexual desire which occurs before menopause and is not due to medical problems, psychiatric problems, or problems within the relationship. It is given by an injection just under the skin of the thigh or abdomen.

Sexual medicine or Psychosexual medicine as defined by Masters and Johnsons in their classic Textbook of Sexual Medicine, is “that branch of medicine that focuses on the evaluation and treatment of sexual disorders, which have a high prevalence rate." Examples of disorders treated with sexual medicine are erectile dysfunction, hypogonadism, and prostate cancer. Sexual medicine often uses a multidisciplinary approach involving physicians, mental health professionals, social workers, and sex therapists. Sexual medicine physicians often approach treatment with medicine and surgery, while sex therapists often focus on behavioral treatments.

Female sexual arousal disorder (FSAD) is a disorder characterized by a persistent or recurrent inability to attain sexual arousal or to maintain arousal until the completion of a sexual activity. The diagnosis can also refer to an inadequate lubrication-swelling response normally present during arousal and sexual activity. The condition should be distinguished from a general loss of interest in sexual activity and from other sexual dysfunctions, such as the orgasmic disorder (anorgasmia) and hypoactive sexual desire disorder, which is characterized as a lack or absence of sexual fantasies and desire for sexual activity for some period of time.

The testosterone patch, brand name Intrinsa among others, was designed to treat female sexual dysfunction.

<span class="mw-page-title-main">Flibanserin</span> Medication

Flibanserin, sold under the brand name Addyi, is a medication approved for the treatment of pre-menopausal women with hypoactive sexual desire disorder (HSDD). The medication improves sexual desire, increases the number of satisfying sexual events, and decreases the distress associated with low sexual desire. The most common side effects are dizziness, sleepiness, nausea, difficulty falling asleep or staying asleep and dry mouth.

<span class="mw-page-title-main">Avanafil</span>

Avanafil is a PDE5 inhibitor approved for erectile dysfunction by the FDA on April 27, 2012 and by EMA on June 21, 2013. Avanafil is sold under the brand names Stendra and Spedra. It was invented at Mitsubishi Tanabe Pharma, formerly known as Tanabe Seiyaku Co., and licensed to Vivus Inc., which partnered with Menarini Group to commercialise Spedra in over forty European countries, Australia, and New Zealand. Metuchen Pharmaceuticals obtained exclusive rights within the United States.

<span class="mw-page-title-main">Herbal viagra</span> Informal name for various herbal products said to treat erectile dysfunction

Herbal viagra is a name that can be given to any herbal product advertised as treating erectile dysfunction. There are many different products advertised as herbal viagra, but with varying ingredients. There are no clinical trials or scientific studies that support the effectiveness of any of these ingredients for the treatment of erectile dysfunction and some products have been found to contain drugs and other adulterants, and have been the subject of FDA and FTC warnings and actions to remove them from the market.

<span class="mw-page-title-main">Phentermine/topiramate</span> Obesity medication

Phentermine/topiramate, sold under the brand name Qsymia, is a combination drug of phentermine and topiramate used to treat obesity. It is used together with dietary changes and exercise. If less than 3% weight loss is seen after 3 months it is recommended the medication be stopped. The weight loss is modest. Effects on heart related health problems or death is unclear.

Liz Canner is an American filmmaker who makes documentaries, digital public art installations and new media projects on human rights issues. Her documentary Deadly Embrace: Nicaragua, The World Bank and the IMF (1995), was one of the first films to look critically at the effects of the International Monetary Fund, World Bank policy and globalization. In 2009 Canner directed Orgasm Inc.: The Strange Science of Female Pleasure (2009), a feature-length investigative documentary on the pharmaceutical industry and women's health.

Vivus is a small pharmaceutical company headquartered in Campbell, California, working in obesity, sleep, and sexual health. Vivus is developing an erectile dysfunction drug, Avanafil, that has completed Phase 3 clinical trials. The drug has been approved for use by the FDA, and will be sold under the trademark name Stendra. Stendra is the first and only oral ED treatment approved to be taken approximately 15 minutes before sexual activity.

<span class="mw-page-title-main">Sulfoaildenafil</span>

Sulfoaildenafil (thioaildenafil) is a synthetic drug that is a structural analog of sildenafil (Viagra). It was first reported in 2005, and it is not approved by any health regulation agency. Like sildenafil, sulfoaildenafil is a phosphodiesterase type 5 inhibitor.

<span class="mw-page-title-main">Apricus Biosciences</span>

Apricus Biosciences, Inc. is a San Diego based biopharmaceutical company advancing innovative medicines in urology and rheumatology.

Pharmaceutical fraud involves activities that result in false claims to insurers or programs such as Medicare in the United States or equivalent state programs for financial gain to a pharmaceutical company. There are several different schemes used to defraud the health care system which are particular to the pharmaceutical industry. These include: Good Manufacturing Practice (GMP) Violations, Off Label Marketing, Best Price Fraud, CME Fraud, Medicaid Price Reporting, and Manufactured Compound Drugs. Examples of fraud cases include the GlaxoSmithKline $3 billion settlement, Pfizer $2.3 billion settlement, and Merck $650 million settlement. Damages from fraud can be recovered by use of the False Claims Act, most commonly under the qui tam provisions which rewards an individual for being a "whistleblower", or relator (law).

Leonore Tiefer is an educator, researcher, therapist, and activist specializing in sexuality, and is a public critic of disease mongering as it applies to sexual life and problems.

<span class="mw-page-title-main">Cindy Eckert</span> American entrepreneur

Cindy Eckert is an American entrepreneur known for founding Sprout Pharmaceuticals. She subsequently founded The Pink Ceiling which invests in companies founded by, or delivering products for, women. In November 2017, Eckert re-acquired Sprout Pharmaceuticals as part of a lawsuit settlement, and the rights to its drug Addyi, from Valeant after Valeant's stock collapsed due to insider trading and price jacking allegations.

<i>The Bleeding Edge</i> 2018 American film

The Bleeding Edge is a 2018 Netflix Original documentary film that investigates the $400 billion medical device industry.

References

  1. News, Staff (2009-05-07). "Hot Docs 2009 Interview: Orgasm, Inc. Director Liz Canner Talks Sex, Drugs, And The Cure For What Ails You". CityNews. Retrieved 2016-03-11.{{cite news}}: |last= has generic name (help)
  2. Catsoulis, Jeannette (2011-02-10). "The Link Between Female Sexuality and Corporate Profits". The New York Times . Retrieved 2016-03-11.
  3. "The Selling of the Female Orgasm". 2010-05-22.